CN105343198A - pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application - Google Patents
pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application Download PDFInfo
- Publication number
- CN105343198A CN105343198A CN201510774230.8A CN201510774230A CN105343198A CN 105343198 A CN105343198 A CN 105343198A CN 201510774230 A CN201510774230 A CN 201510774230A CN 105343198 A CN105343198 A CN 105343198A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- herba
- chemotherapy
- bone marrow
- myelosuppressive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression discloses a pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application. The pharmaceutical composition is prepared from following traditional Chinese medicinal materials in parts by weight: Herba Polygalae Japonicae 29-46 parts and Herba Sarcopyramis Nepalensis 30-60 parts. In terms of chemotherapy-caused bone marrow suppression, the pharmaceutical composition can prevent the reduction in leukocyte and even increase the number of neutrophils, thus improving chemotherapeutic effect on cancers, prolonging life of a patient and improving living quality.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to a kind of myelosuppressive medical composition and its use prevented and treated chemotherapy and cause.
Background technology
The hemopoietic system of human body is made up of the hematopoietic cell of a small amount of marrow hemopoietic stem cells and different development stage different series, the harmful factor produced various physical chemistry and internal metabolism is very responsive, such as body is exposed to radiation or some chemotherapeutics, and accept radiotherapy clinically, the patient of chemotherapy very easily sustains damage and occurs bone marrow depression in various degree, show as that peripheral blood leucocyte reduces, bone marrow proliferation function reduction even aplastic anemia occurs, serious harm even threat to life is caused to the life quality of patient.Once suffer from cancer, patient will use antitumor drug within considerable time, and most antitumor drug all can cause bone marrow depression in various degree, and main manifestations is leukopenia, and especially Neutrophilic granulocytopenia is the most remarkable.Current Radiotherapy chemotherapy remains means the most frequently used in oncotherapy, but the complication such as the bone marrow hematogenesis suppression caused after treatment become the major reason affecting life in patients.Some oncotherapy assistant chemical medicines with clear and definite curative effect itself will produce more untoward reaction after a procedure, add the misery of patient.Many medical personnels are being devoted to find some effectively but the infringement that brings to resist Radiotherapy chemotherapy of the few medicines of side reaction.
Various somatomedin is given, to increase the propagation of hematopoietic cell clinically at present to occurring that mostly bone marrow depression is to adopt.The hemopoietic growth factor of the gene recombinaton of just having gone on the market this year is as SHENGBAINENG (rhGM-GSF), G-CSF (rhG-CSF) etc., be used for leukocyte increasing Be very effective, but because of expensive, not most patient can bear, and rhGM-GSF, rhG-CSF cannot use while chemotherapy, also cannot preventing to use, can only use when there is leukopenia, otherwise can produce by toxic side effect.In addition, gene therapy such as the gene therapies such as IL-6, IL-3 of hemopoietic growth factor are still in the animal experiment stage, when autogenous bone marrow suppresses to be everlasting high-dose chemotherapy with the use of, but be difficult to repeatedly apply.Therefore, find the side reaction of a kind of safe, effective, inexpensive method antagonism chemotherapy, raise Leukocytes after Chemotherapy, for the chemotherapy effect improving tumor, extend cancer patient's life cycle, improving life quality has very important meaning.
The mankind in the exploratory development of anticancer ancillary drug, Chinese medicine, crude drug more and more highlight its drug effect good, without additive, untoward reaction is few and the advantage such as aboundresources, causes the attention of people.Therefore, find and develop a kind of myelosuppressive Chinese Traditional Medicines prevented and treated chemotherapy and cause, this seems particularly important.
Summary of the invention
The object of the invention is to, by furtheing investigate the leukemic folk remedy for the treatment of, provide one to prevent and treat chemotherapy and cause myelosuppressive medicine, this medicine has ideal biological activity in promotion hemopoietic function etc.
The object of the present invention is achieved like this:
The myelosuppressive pharmaceutical composition of a kind of control, described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Polygalae Japonicae 29-46 part, Herba Sarcopyramis nepalensis 30-60 part.
Further preferably, the myelosuppressive pharmaceutical composition of control is prepared from by the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Herba Polygalae Japonicae 34-38 part, Herba Sarcopyramis nepalensis 46-52 part.
Again further preferably, the myelosuppressive pharmaceutical composition of control is prepared from by the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Herba Polygalae Japonicae 36 parts, Herba Sarcopyramis nepalensis 50 parts.
It should be noted that, in the myelosuppressive pharmaceutical composition of preparation control of the present invention, traditional Chinese medicinal material raw materials Herba Polygalae Japonicae wherein selects the aerial parts of Polygalaceae polygala Herba Polygalae Japonicae PolygalajaponicaHoutt..
The myelosuppressive pharmaceutical composition of control of the present invention, wherein Chinese medicinal material extract active component has carried out relevant animal test in gavage mode, and result medicine is remarkable through gastrointestinal absorption, and therefore described pharmaceutical composition can be oral formulations.Wherein said oral formulations comprises tablet, capsule, granule.According to the common process of formulation art, those skilled in the art is easy to adjuvant available on Chinese medicine and pharmaceutics is prepared into conventional solid orally ingestible, as granule, tablet, capsule.Wherein, available on pharmaceutics adjuvant comprises filler, disintegrating agent, binding agent, correctives, lubricant etc.
Leukocyte comprises neutrophilic granulocyte, eosinophilic granulocyte and basophilic granulocyte, and leukocyte is by bone marrow hematogenesis, clinically; tumour patient is after accepting chemotherapy; usually there will be bone marrow depression, thus peripheral white blood cell amount is reduced, neutrophilic granulocyte quantity reduces.Human peripheral blood neutrophilic granulocyte accounts for the 50-70% of total white blood cells, and it increases and lower the change directly affecting total white blood cells, and namely neutrophilic granulocyte increases, and leukocyte increases thereupon; Neutrophilic granulocyte lowers, and total white blood cells also lowers thereupon.Both dependencys quantitatively also show the concordance in meaning, i.e. the meaning of neutrophilic granulocyte increase and decrease with the meaning of the increase and decrease of total white blood cells is consistent substantially.The present invention is confirmed by animal vivo test, and the decocting liquid of Herba Polygalae Japonicae and Herba Sarcopyramis nepalensis can significantly improve the quantity of Leukocytes after Chemotherapy, especially has the biological activity improving neutrophilic granulocyte quantity.Therefore, another object of the present invention is to provide a kind of pharmaceutical applications, that is: the feedstock composition that Herba Polygalae Japonicae and Herba Sarcopyramis nepalensis form is preparing the purposes of preventing and treating in myelosuppressive medicine.Wherein, the preferred peripheral blood leucocyte decline of described bone marrow depression, hypoplastic bone marrow or aplastic anemia.
Preventing and treating in the bone marrow depression that chemotherapy causes, pharmaceutical composition of the present invention can prevent leukocyte to reduce, and even improves the granulocytic quantity in center, thus improves the chemotherapy effect of cancer, extends the life cycle of patient, improves life quality; It can use while other medicines chemotherapy, also can prevent to use.
Detailed description of the invention
Be below preparation embodiment of the present invention and effect test example, technical scheme of the present invention and technique effect are further explained.It should be noted that, the traditional Chinese medicinal material raw materials that the embodiment of the present invention adopts has following source: Herba Polygalae Japonicae selects the dry aerial parts of Polygalaceae polygala Herba Polygalae Japonicae PolygalajaponicaHoutt..Herba Sarcopyramis nepalensis selects the dry herb of Melastomateae plants Herba Sarcopyramis nepalensis SarcopyamisnepalensisWall..
the preparation of embodiment 1 Chinese medicine extract
Take Herba Polygalae Japonicae 0.36kg, Herba Sarcopyramis nepalensis 0.50kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1h, pull out medical material put multi-functional extractions filling in decoct with water extraction secondary, add up the water of medical material 16 times amount for the first time, decoct 2h, get decocting liquid, filter, second time adds up the water of medical material 12 times amount, decocts 1.5h, get twice decocting liquid to merge, filter, heating is concentrated into thick paste, about 50 DEG C oven dry, pulverize, cross 100 mesh sieves, obtain Chinese medicine extract.
the preparation of embodiment 2 Chinese medicine oral liquid
Take Herba Polygalae Japonicae 0.40kg, Herba Sarcopyramis nepalensis 0.40kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1h, pull out medical material put multi-functional extractions filling in decoct with water secondary, add up the water of medical material 20 times amount for the first time, decoct 2h, get decocting liquid, filter, second time adds up the water of medical material 20 times amount, decocts 1h, get twice decocting liquid to merge, filter, heating is concentrated into every 1ml solution and is equivalent to 4g crude drug, puts 5 DEG C of refrigerator deepfreeze 24h, cold preservation liquid is filtered, obtains medicinal liquid.
the myelosuppressive controlling experiment research that embodiment 3 Chinese medicine extract causes mice with tumor chemotherapy
(1) the copying of tumor model mice: mouse ascites tumor S180 cell culture in RPMI-1640,37 DEG C, 5%CO
2lower cellar culture, on average goes down to posterity once in every two days, and being prepared into density to normal saline during exponential phase is 3.0 × 10
7individual/ml single cell suspension, aseptically be injected in mouse peritoneal, inoculate latter 7 days and see the obvious enlargement of mouse peritoneal, now, de-neck is put to death, and puts into the beaker filling 75% ethanol and soaks 2 ~ 3 minutes, the mice after sterilization is put into superclean bench, expose abdominal part, put into aseptic reagent bottle by asepsis injector extraction ascites for subsequent use.Above-mentioned ascites trypan blue is counted, with normal saline dilution, adjustment cell number to 2.0 × 10
7individual/ml, is inoculated in the right oxter of mice of body weight 18 ~ 22g, every 0.2ml.
(2) grouping and administration: KM mice in postvaccinal 7 week age is divided into following three groups at random: model control group, docetaxel group, Chinese drug-treated group, often organize 12, male and female half and half, normal solid feedstuff of feeding, freely drinks water.Each treated animal specifically gives corresponding tested material by following dosage: the distilled water of model control group gavage same volume; Docetaxel group tail vein injection docetaxel 75mg/m
2/ d(dosage); Chinese drug-treated group mice is at tail vein injection docetaxel 75mg/m
2on the basis of/d, then gavage gives the Chinese medicine extract 480mg/kg/d prepared by the formulation and technology of above-described embodiment 1 Indole-3-carbinol.The administration volume of docetaxel is 20ml/kg, and the administration volume of Chinese medicine extract is 10ml/kg.Each group of every day is administered once, altogether two weeks.In process of the test, observe animal diet followed, survival condition and behavioral activity every day, after off-test, anesthesia is dissected, and abdomen cardinal vein gets blood, surveys routine blood test, investigates total white blood cells and neutrophilic granulocyte sum.Result of the test is in table 1.
(3) test result analysis: compared with model group, total white blood cells and the neutrophilic granulocyte number of docetaxel group all significantly reduce, have pole significant difference (
p< 0.01); Compared with docetaxel group, the total white blood cells of Chinese drug-treated group and neutrophilic granulocyte number significance increase (
p< 0.01); This illustrates that Chinese medicine extract of the present invention and docetaxel are combined for synergistic antitumor simultaneously, and it effectively can alleviate the bone marrow depression (see table 1) that docetaxel chemotherapy causes.
Table 1 each group murine interleukin and neutrophilic granulocyte number ratio are comparatively
| Group | Sample size | Leukocyte (10 9Individual/L) | Neutrophilic granulocyte (10 9Individual/L) |
| Model group | 12 | 3.51±0.29 | 1.31±0.15 |
| Docetaxel group | 12 | 2.39±0.38 * | 0.72±0.23 * |
| Chinese drug-treated group | 12 | 3.37±0.41 ￥ | 1.26±0.22 ￥ |
Docetaxel group compares with model group,
* p< 0.01; Chinese drug-treated group compares with docetaxel group,
$ p< 0.01.
Claims (8)
1. prevent and treat a myelosuppressive pharmaceutical composition, it is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Polygalae Japonicae 29-46 part, Herba Sarcopyramis nepalensis 30-60 part.
2. the myelosuppressive pharmaceutical composition of control according to claim 1, is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Polygalae Japonicae 34-38 part, Herba Sarcopyramis nepalensis 46-52 part.
3. the myelosuppressive pharmaceutical composition of control according to claim 2, is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Polygalae Japonicae 36 parts, Herba Sarcopyramis nepalensis 50 parts.
4. the myelosuppressive pharmaceutical composition of control according to claim 1 or 2 or 3, is characterized in that: described traditional Chinese medicinal material raw materials Herba Polygalae Japonicae selects the aerial parts of Polygalaceae polygala Herba Polygalae Japonicae PolygalajaponicaHoutt..
5. the myelosuppressive pharmaceutical composition of control according to claim 1 or 2 or 3, is characterized in that: described pharmaceutical composition is oral formulations.
6. the myelosuppressive pharmaceutical composition of control according to claim 5, is characterized in that: described oral formulations comprises tablet, capsule, granule.
7. the feedstock composition that Herba Polygalae Japonicae and Herba Sarcopyramis nepalensis form is preparing the purposes of preventing and treating in myelosuppressive medicine.
8. purposes according to claim 7, is characterized in that, described bone marrow depression is the bone marrow depression that chemotherapy causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510774230.8A CN105343198A (en) | 2015-11-13 | 2015-11-13 | pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510774230.8A CN105343198A (en) | 2015-11-13 | 2015-11-13 | pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343198A true CN105343198A (en) | 2016-02-24 |
Family
ID=55319358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510774230.8A Pending CN105343198A (en) | 2015-11-13 | 2015-11-13 | pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343198A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840528A (en) * | 2015-05-28 | 2015-08-19 | 周玉梅 | Pharmaceutical composition for preventing and treating myelosuppression and use of pharmaceutical composition |
-
2015
- 2015-11-13 CN CN201510774230.8A patent/CN105343198A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840528A (en) * | 2015-05-28 | 2015-08-19 | 周玉梅 | Pharmaceutical composition for preventing and treating myelosuppression and use of pharmaceutical composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102440986B (en) | Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals | |
| CN102091315B (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN102145159A (en) | Ginger and elecampane composition, preparation method of ginger and elecampane composition and use of ginger and elecampane composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN101264311B (en) | Natural pharmaceutical composition, its preparation and its attenuation synergistic use in cancer radiotherapy and chemotherapy | |
| CN102091314B (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN111870609A (en) | Intestinal flora regulator and application thereof | |
| CN104840528A (en) | Pharmaceutical composition for preventing and treating myelosuppression and use of pharmaceutical composition | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN101229175A (en) | Medical applications of couple protopanoxadiol derivatives and compound body thereof | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN1321696C (en) | Composition and method for reducing side effects of indole-3-carbinol and derivatives | |
| CN103027906B (en) | The application of arctigenin in treatment anemia disease | |
| CN105343198A (en) | pharmaceutical composition for controlling chemotherapy-caused bone marrow suppression and its application | |
| CN102125571A (en) | Dammarane aglycon compound and application thereof | |
| CN102091313B (en) | Composition of perilla leaf and ginger, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| TWI601535B (en) | Use of compositions of water/alcohol extracts of antrodia cinnamomea cut-log cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| CN109662968A (en) | The liter white preparation of -5 α androstane hydride compounds of carbon loss containing A- and its application | |
| CN111558045A (en) | Medicine composition for treating lung cancer | |
| CN102552847B (en) | Ginger and inula flower composition for reducing vomiting caused by cancer chemotherapy and increasing curative effect for chemotherapy and preparing method thereof | |
| CN104688722A (en) | Use of anhydroicaritin in preparation of myelosuppression prevention or treatment medicines | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN100420445C (en) | Fatty cream composition for maligant splanchnocoele hydrops and its preparing method | |
| CN102652745B (en) | Application of indole-3-carbinol (I3C) or dimer thereof to preparation of drugs for treating bone marrow suppression | |
| CN103893166A (en) | Pharmaceutical composition for resisting chemotherapy induced bone marrow suppression and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |